Table 2.
Characteristics | mPFS | 95% CI | ORR | 95% CI |
---|---|---|---|---|
Total | 4.2 months | 0.3, 8.1 | 27.2% | 6.0, 61.0 |
PD-L1 | ||||
PD-L1 + | 5.7 months | 0.3, 11.1 | 33.3% | 8.0, 90.6 |
PD-L1 − | 2.1 months | 0.1, 5.4 | 25.0% | 3.2, 65.1 |
Line of anti-PD-1 inhibitor | ||||
First-line | 5.7 months | 0.1, 26.7 | 40.0% | 5.3, 85.3 |
Second/beyond line | 2.1 months | 1.5, 2.7 | 16.7% | 0.4, 64.1 |
HPV status | ||||
HPV + | 1.8 months | 0.7, 2.9 | 0% | N/A |
HPV − | 5.7 months | 0.1, 13.4 | 37.5% | 8.5, 75.5 |